Keros Therapeutics announced initial topline results from its Phase 1 clinical trial of KER-065 in healthy volunteers, with the stock trading under the ticker $KROS. Corcept Therapeutics reported that its Phase 3 ROSELLA trial of relacorilant for platinum-resistant ovarian cancer met its primary endpoint, resulting in a notable increase of approximately 50% in its stock price, traded as $CORT. Vaxcyte also revealed positive topline results from its VAX-24 infant Phase 2 dose-finding study, although its stock, $PCVX, saw a decline of 32.3% in pre-market trading. Additionally, Kairos Pharma announced the completion of enrollment for the safety arm of its Phase 2 clinical trial of ENV105 in metastatic, castration-resistant prostate cancer, with the stock symbol $KAPA. BiomX disclosed positive topline results from a Phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis, trading under the ticker $PHGE.